Sub-Saharan South Africa Pharmaceuticals Capital

CFBANQUE Investment confirms the BB rating assigned to Sub-Saharan South Africa Pharmaceuticals Capital (REN0493.JO), an operator in the Pharmaceuticals sector based in South Africa. This credit opinion reflects a speculative profile with heightened sensitivity to the economic cycle, refinancing conditions and input price volatility.

From a fundamental standpoint, the issuer posts an EBITDA margin of 38.1% which sits at the upper end of the sector range and evidences robust pricing power and exhibits an elevated net leverage of 4.20x EBITDA, which reduces financial flexibility in the event of a cyclical downturn. With revenues of $8.86B and a market capitalisation of $14.35B, Sub-Saharan South Africa Pharmaceuticals Capital commands a significant economic footprint within its domestic market.

Our proprietary models assign a Debt Capacity score of 359/1000, an Investment score of 525/1000 and an ESG & Governance score of 930/1000, reflecting a debt coverage that requires close monitoring, a measured investment potential and governance standards aligned with best market practice.

The Positive outlook reflects our expectation of a gradual improvement in the credit profile over a 12 to 18 month horizon, subject to the execution of the strategic plan communicated by the issuer. This analysis stems from the combined review of our quantitative models and the qualitative judgement of the CFBANQUE Investment rating committee, and may be updated in line with the evolution of fundamentals or the regional macroeconomic environment.